SBL
INO icon

Sargent Bickham Lagudis’s Inovio Pharmaceuticals INO Stock Holding History

Sargent Bickham Lagudis’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44
Closed -$4K – 982
2021
Q3 		$4K Hold
44
– – ﹤0.01% 830
2021
Q2 		$5K Hold
44
– – ﹤0.01% 798
2021
Q1 		$5K Hold
44
– – ﹤0.01% 788
2020
Q4 		$5K Hold
44
– – ﹤0.01% 737
2020
Q3 		$6K Hold
44
– – ﹤0.01% 647
2020
Q2 		$14K Hold
44
– – ﹤0.01% 533
2020
Q1 		$4K Buy
+44
New +$2.71K ﹤0.01% 655

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sargent Bickham Lagudis's INO Position: Q4 2021 in Review

Sargent Bickham Lagudis sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 44 shares — an estimated $4K sold.

Sargent Bickham Lagudis first reported a position in INO in Q1 2020 and held it in 7 quarters. The position peaked at $14K in Q2 2020. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

  • Sargent Bickham Lagudis reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 44 Inovio Pharmaceuticals shares in Q4 2021, an estimated $4K.
  • Sargent Bickham Lagudis first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • Sargent Bickham Lagudis's Inovio Pharmaceuticals position peaked at $14K in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2021, filed 18 Jan 2022.